Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers.

Predictors of exposure, therapeutic and adverse effects of atezolizumab used in the treatment of advanced cancers.

Advanced cancers are difficult to treat. Atezolizumab is an immunotherapy which are an important emerging treatment option for advanced cancer patients. However, response and toxicity to immunotherapies is highly unpredictable, with up to 40% of the patients who initiate atezolizumab not responding, and 40% experiencing serious toxicity. Using the diverse range of data collected from clinical trials, it is possible to develop clinical tools that enable improved prediction of therapeutic and adverse outcomes of patients using atezolizumab in the treatment of advanced cancers. Being able to identify the expected response and adverse effect profile may enable patients and clinicians to make better decisions regarding whether to commence, continue, discontinue or change dosing of atezolizumab.

[{ "PostingID": 14578, "Title": "ROCHE-GO29293", "Description": "A Study of Atezolizumab in Participants With Locally Advanced or Metastatic Urothelial Bladder Cancer (Cohort 1)" },{ "PostingID": 14579, "Title": "ROCHE-GO28915", "Description": "A Study of Atezolizumab Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum-Containing Therapy" },{ "PostingID": 14580, "Title": "ROCHE-GO28625", "Description": "A Study of Atezolizumab in Participants With Programmed Death-Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) [FIR]" },{ "PostingID": 14581, "Title": "ROCHE-GO28754", "Description": "A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer" },{ "PostingID": 14582, "Title": "ROCHE-GO28753", "Description": "A Randomized Phase 2 Study of Atezolizumab (an Engineered Anti-PDL1 Antibody) Compared With Docetaxel in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Platinum Therapy - \"POPLAR\"" }]